News
Announces operational restructuring
Maria Karlsson Osipova
2026-03-27
10:10 CET
Yesterday, Lifecare announced a strategic operational restructuring. As part of this shift, the company will centralise operations (manufacturing to be established in Bergen and chemistry-related activities consolidated in Bristol). The German subsidiary will be discontinued in its entirety. The company stated that the restructuring is aimed at lowering operating costs, increasing efficiency, reducing organisational complexity, and enabling faster execution towards production. While it expects material opex reductions over time, one-off restructuring costs are to be expected.
Our take. We view the restructuring as strategically positive, but it adds operational complexity at an already challenging time. As highlighted in our previous comments, the key milestone (potential FIH trial initiation in 2026) remains dependent on regulatory approval. Following NOMA’s rejection of the FIH application, approval is uncertain and we await clarity on the next steps and resubmission timing.
We have contacted management, who provided some incremental colour. One-offs are expected over 6–12 months, with the transition largely completed within c12 months. No certification delays are expected, and production will rely on existing off-the-shelf technologies. Capex for Bergen remains unclear, with a gradual, needs-based build-out. With Germany accounting for c50% of FTEs and an assumed one-third reduction at group level, we estimate personnel costs could decline by ~1/3 by 2027, implying c15% lower opex, all else being equal. However, execution risk remains, and visibility on one-off costs is limited. We have not yet reflected these assumptions in our model. Overall, while strategically sound, regulatory uncertainty and operational complexity keep us cautious. Improved visibility on timelines, funding, and FIH progress will be key near-term to restore confidence in the stock in our view.